Genmab Combination Shows 28.2-Month Median Survival in Phase 2 Trial
Genmab said its petosemtamab-pembrolizumab combination achieved median survival of 28.2 months in a Phase 2 head and neck cancer trial.
Genmab said its petosemtamab-pembrolizumab combination achieved median survival of 28.2 months in a Phase 2 head and neck cancer trial.